PMID- 24668480
OWN - NLM
STAT- MEDLINE
DCOM- 20140826
LR  - 20161125
IS  - 0171-2004 (Print)
IS  - 0171-2004 (Linking)
VI  - 220
DP  - 2014
TI  - Huntington's disease.
PG  - 357-409
LID - 10.1007/978-3-642-45106-5_14 [doi]
AB  - Changes in the level and activity of brain-derived neurotrophic factor (BDNF) 
      have been described in a number of neurodegenerative disorders since early 1990s. 
      However, only in Huntington disease (HD) gain- and loss-of-function experiments 
      have mechanistically linked these abnormalities with the genetic defect.In this 
      chapter we will describe how huntingtin protein, whose mutation causes HD, is 
      involved in the physiological control of BDNF synthesis and transport in neurons 
      and how both processes are simultaneously disrupted in HD. We will describe the 
      underlying molecular mechanisms and discuss pre-clinical data concerning the 
      impact of the experimental manipulation of BDNF levels on HD progression. These 
      studies have revealed that a major loss of BDNF protein in the brain of HD 
      patients may contribute to the clinical manifestations of the disease. The 
      experimental strategies under investigation to increase brain BDNF levels in 
      animal models of HD will also be described, with a view to ultimately improving 
      the clinical treatment of this condition.
FAU - Zuccato, Chiara
AU  - Zuccato C
AD  - Department of Biosciences and Centre for Stem cell Research, Universita degli 
      Studi di Milano, Via Viotti 3/5, 20133, Milan, Italy, chiara.zuccato@unimi.it.
FAU - Cattaneo, Elena
AU  - Cattaneo E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Handb Exp Pharmacol
JT  - Handbook of experimental pharmacology
JID - 7902231
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (HTT protein, human)
RN  - 0 (Huntingtin Protein)
RN  - 0 (Nerve Tissue Proteins)
SB  - IM
MH  - Animals
MH  - Brain Chemistry
MH  - Brain-Derived Neurotrophic Factor/analysis/*genetics
MH  - Genetic Therapy
MH  - Humans
MH  - Huntingtin Protein
MH  - Huntington Disease/*genetics/therapy
MH  - Mutation
MH  - Nerve Tissue Proteins/genetics
MH  - Polymorphism, Genetic
MH  - Promoter Regions, Genetic
EDAT- 2014/03/29 06:00
MHDA- 2014/08/27 06:00
CRDT- 2014/03/27 06:00
PHST- 2014/03/27 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/08/27 06:00 [medline]
AID - 10.1007/978-3-642-45106-5_14 [doi]
PST - ppublish
SO  - Handb Exp Pharmacol. 2014;220:357-409. doi: 10.1007/978-3-642-45106-5_14.